

ESTTA Tracking number: **ESTTA1297361**

Filing date: **07/14/2023**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Applicants	Amgen Inc.
Application serial no.	97353493
Application filing date	04/08/2022
Mark	PAVBLU
Date of publication	04/04/2023
Potential opposer's Correspondence information	MAURY M. TEPPER, III TEPPER & EYSTER, PLLC 3724 BENSON DR RALEIGH, NC 27609 UNITED STATES Primary email: mtepper@teiplaw.com Secondary email(s): athompson@teiplaw.com 9198618903

60 Day Request for Extension of Time to Oppose Upon Consent

Pursuant to 37 C.F.R. Section 2.102, Novartis AG, CH-4002, BASEL, 4002, SWITZERLAND respectfully requests that he/she/it be granted an additional 60-day extension of time to file a notice of opposition against the above-identified mark with applicant's consent.

The time within which to file a notice of opposition is set to expire on 08/02/2023. Novartis AG respectfully requests that the time period within which to file an opposition be extended until 10/01/2023.

Respectfully submitted,
/Maury M. Tepper, III/
Tepper III, Maury M
mtepper@teiplaw.com
07/14/2023